Goldman Sachs raises Grindr stock price target on growth outlook

Goldman Sachs raised its Grindr price target to $20 from $19 and maintained a Buy rating after the company raised its 2026 outlook and issued preliminary 2027 guidance above expectations. Q3 2026 revenue was $141 million, up 22% year over year and above the $134.99 million forecast, while adjusted EBITDA was $62 million. Shares were unchanged after hours as investors weighed growth prospects against one-time legal costs and challenges in the new health-care business.

Analysis

The key signal is not the higher analyst target; it is whether new products can turn user engagement into durable, incremental revenue without diluting the unusually strong core economics. The unchanged after-hours reaction despite a beat and higher outlook suggests the market is discounting execution quality, legal-cost noise, or the bridge from current products to 2027 guidance. That leaves room for upside if reported product traction resolves those doubts, but the consensus Buy stance and tight target range also imply limited informational edge from the broker action itself.

Over the next 1–3 months, focus on revenue contribution and adoption evidence for Edge and Freddie, the composition of 2027 growth, and whether adjusted EBITDA tracks revenue or is absorbed by investment and legal costs. Over 6–18 months, successful health-and-wellness expansion could broaden monetization; failure would leave growth dependent on the core app and make the current growth multiple more vulnerable. Match Group and Bumble are relevant competitive benchmarks for user monetization, though their business mix is not directly comparable. The contrarian risk is treating preliminary guidance and management optimism as proof of product-market fit; absent cohort, retention, and product-level revenue disclosures, that remains unverified.

Key Decisions for Investors

• Do not chase the Goldman target revision as a standalone catalyst. Consider a staged long in GRND only if subsequent disclosures validate Edge/Freddie adoption and revenue contribution; otherwise wait for the next earnings update.
• Track 2027 guidance components, product-level growth or usage metrics, and adjusted EBITDA conversion. A guide cut, weakening core growth, or rising costs without measurable product traction would falsify the growth thesis and warrant reducing or avoiding exposure.
• Treat legal costs and the health-care initiative as separate underwriting items: verify whether costs are recurring and whether the new business has measurable commercial traction before assigning it meaningful value.
• Use Match Group and Bumble as operating comparators, not automatic hedges. A relative-value trade needs current valuation, growth, and user-monetization data; the article does not establish that GRND is mispriced versus peers.